收藏切换
Effects of bevacizumab combined with chemotherapy regimen on NLR, PLR, NWR, LWR and lymphocyte subpopulations in patients with lung adenocarcinoma
收藏切换
Le YING1, Yu TAO2, Hongbo YANG1, Nan SONG1, Yuzhu YANG1, *
World Clinical Drug | 2025, 46(3) : 271 - 276
Less
收藏切换
World Clinical Drug | 2025, 46(3): 271-276
• Article •
Effects of bevacizumab combined with chemotherapy regimen on NLR, PLR, NWR, LWR and lymphocyte subpopulations in patients with lung adenocarcinoma
Full
Le YING1, Yu TAO2, Hongbo YANG1, Nan SONG1, Yuzhu YANG1, *
Affiliations
  • 1.Department of Oncology, Baozhang Hospital, Bozhou Anhui, Bozhou 236705, Anhui Province, China
  • 2.Department of Oncology, Lu'an People's Hospital of Anhui Province, Lu'an 237000, Anhui Province, China
Published: 2025-03-10 doi: 10.13683/j.wph.2025.03.011
Outline
收藏切换
Objective

To investigate the effects of bevacizumab combined with chemotherapy regimen on neutrophil-to-lymphocyte ratio(NLR), platelet-to-lymphocyte ratio(PLR), utrophil-to-lymphocyte ratio(NWR), lymphocyte-to-white blood cell ratio(LWR) and lymphocyte subpopulations in patients with lung adenocarcinoma.

Methods

A total of 102 patients with lung adenocarcinoma who received treatment in Baozhang Hospital from March 2022 to March 2024 were randomly divided into study group and control group, with 51 cases in each group. Both groups were treated with programmed death receptor 1 inhibitor+pemetrexed+platinum, while the study group was additionally treated with bevacizumab. The therapeutic efficacy, blood routine, lymphocyte subsets, Karnofsky performance status(KPS) score and the occurrence of adverse reactions were compared between the two groups after treatment.

Results

After treatment, the total effective rate of the study group was higher than that of the control group(82.35% vs. 60.78%, P<0.05). The levels of NLR, PLR, NWR and LWR in both groups were decreased compared with those before treatment, and the study group was lower than the control group(P<0.05). The levels of natural killer cells and cluster of differentiation(CD)4+/CD8+in both groups were increased compared with those before treatment, and the study group was higher than the control group(P<0.05). The KPS score of the study group was higher than that of the control group[(89.91±6.62) points vs.(83.44±8.93) points, P<0.05]. There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).

Conclusion

Bevacizumab as an adjuvant therapy for lung adenocarcinoma can enhance the efficacy, improve the levels of NLR, PLR, NWR, LWR and lymphocyte subpopulations in patients, and does not increase the occurrence of adverse reactions.

bevacizumab  /  lung adenocarcinoma  /  neutrophil-to-lymphocyte ratio  /  platelet-to-lymphocyte ratio  /  utrophil-to-lymphocyte ratio  /  lymphocyte-to-white blood cell ratio  /  lymphocyte subpopulation
应乐, 陶玉, 杨宏博, 宋楠, 杨玉柱. 贝伐珠单抗联合化疗方案对肺腺癌患者NLR、PLR、NWR、LWR及淋巴细胞亚群的影响. 世界临床药物, 2025 , 46 (3) : 271 -276 . DOI: 10.13683/j.wph.2025.03.011
Le YING, Yu TAO, Hongbo YANG, Nan SONG, Yuzhu YANG. Effects of bevacizumab combined with chemotherapy regimen on NLR, PLR, NWR, LWR and lymphocyte subpopulations in patients with lung adenocarcinoma[J]. World Clinical Drug, 2025 , 46 (3) : 271 -276 . DOI: 10.13683/j.wph.2025.03.011
Year 2025 volume 46 Issue 3
47
9
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.03.011
  • Receive Date:2025-01-28
  • Online Date:2026-11-10
  • Published:2025-03-10
Article Data
Affiliations
History
  • Received:2025-01-28
Affiliations
    1.Department of Oncology, Baozhang Hospital, Bozhou Anhui, Bozhou 236705, Anhui Province, China
    2.Department of Oncology, Lu'an People's Hospital of Anhui Province, Lu'an 237000, Anhui Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.03.011
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT